The inhibition of the mevalonate pathway (such as using statins, e.g., cerivastatin), abrogating RhoA geranylgeranylation (e.g., with GGTI-298), or RhoA activity (e.g., with C3 toxin) can destabilize mutp53, reducing its oncogenic effects and suppressing cancer cell proliferation and metastasis [59]. The gene discussed is RHOA; the disease is cancer.